autologous IL-12/multi-targeted primed T cells RPTR 168

{
  "id": "MLC-T-ONC-011661",
  "term": "autologous IL-12/multi-targeted primed T cells RPTR 168",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of genetically modified, multi-antigen-targeted autologous T lymphocytes, tethered with the human immunostimulatory cytokine interleukin-12 (IL-12), with potential immunostimulating and antineoplastic activities. RPTR 168 is prepared from monocyte-derived dendritic cells (moDCs) that are pulsed with five tumor-associated antigens (TAAs) to expand cytotoxic T lymphocytes (CTLs) that are subsequently loaded with IL-12. Upon administration, the autologous IL-12/multi-targeted primed T cells RPTR 168 specifically target tumor cells expressing the five TAAs, which lead to a specific cytotoxic T-lymphocyte (CTL)-mediated killing of these tumor cells. In addition, IL-12 expression activates the immune system by promoting the secretion of interferon-gamma (IFN-g), activating natural killer cells (NKs), and inducing CTL responses, which may further increase tumor cell death and decrease tumor cell proliferation.",
  "synonyms": [
    "autologous IL-12-expressing MTC RPTR 168",
    "autologous IL-12/multi-targeted primed T lymphocytes RPTR 168",
    "PRIME IL-12"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-il-12-multi-targeted-primed-t-cells-rptr-168/"
}